Chronic Kidney Disease Anemia – Global Drug Forecast and Market Analysis to 2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Anemia is a common complication of chronic kidney disease (CKD) that is most frequently attributed to insufficient synthesis of erythropoietin (EPO) due to kidney damage. CKD anemia is highly prevalent among CKD patients and its prevalence increases as CKD progresses, affecting more than half of patients in stage V. Over the last 20 years, the CKD anemia market has grown exponentially. Treatment of CKD anemia was significantly improved following the introduction of recombinant human EPO (rHuEPO), and ESAs have dominated the disease space as the standard of care.

The CKD anemia market is relatively well-established; many physicians believe that the existing therapies, namely ESAs, effectively control anemia for most patients. However, despite several options, there is still room for improvement and innovation within the space. GlobalData has identified a variety of unmet needs. While ESAs have improved the treatment for patients with CKD anemia, their safety profiles are not ideal. As injectable ESAs often stimulate EPO to supraphysiologic levels, which subsequently associates their use with increased cardiovascular (CV) risks, safer treatment options for CKD anemia is currently the most significant unmet need for the condition.

Major drivers of growth in the CKD anemia market over the forecast period include: the launch and uptake of novel hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) drug class across all markets covered in the report will drive the growth of the CKD anemia market. GlobalData expects this novel class of drugs, which includes several recently approved and late-stage candidates, to have steady uptake across the 8MM, as they are anticipated to address some of the main unmet needs in the space. Market growth will also be driven by the launch of several oral and IV iron products in addition markets.

GlobalData expects the market to increase to $6.6B in 2029 at a Compound Annual Growth Rate (CAGR) of 3.4%. Furthermore, the China CKD anemia market is expected to experience the highest growth, increasing to $962M (14.6% of global market share) by 2029, at a CAGR of 9.9%. Sales in the other regions are also expected to increase by the end of the forecast period. This global growth is driven mainly by the anticipated approval and launch of HIF-PHIs but will likely be tempered by marked biosimilar erosion of several top-selling currently marketed branded erythropoiesis-stimulating agents (ESAs).

KEY QUESTIONS ANSWERED

Despite the existence well-established treatment options for treating CKD anemia, a few—yet significant—unmet needs remain.
Which unmet needs are the most pressing in the 8MM?
Where should pharmaceutical companies focus drug development efforts in order to become a significant player in the space?

Sales in the CKD anemia market are dominated by the highly lucrative ESA class of drugs
What factors will shape the competitive treatment landscape?
Will ESAs maintain their strong market position?
How much pressure will they face from new entrants?

Several HIF-PHIs have recently been marketed or are soon expected to gain their first approval among the 8MM:
Which companies are leading the way with their own HIF-PHI?
What do KOLs say about their clinical and commercial positioning?
How are they expected to shape the future CKD anemia treatment paradigm?

Scope

Overview of CKD anemia including epidemiology, disease etiology and management.

Topline CKD anemia drugs market revenue (including ESAs and iron therapies), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.

Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5U, Japan and China over the 10-year forecast period.

Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global angina pectoris therapeutics market. Insightful review of the key industry drivers, restraints and challenges.

Key Highlights

Despite therapies currently available to anemia in CKD patients, there is still room for improvement within the space. Global sentiment among KOLs included the growing need for safer treatment options, less burdensome drug administration, and the importance of novel therapies for patients resistant to ESA treatment.

Although ESAs are forecast to remain the highest-grossing drug class at the end of the forecast period, this drug class has a negative CAGR of 2.9%. This decline in sales can be largely attributed the launch of HIF-PHIs and biosimilar competition.

These market dynamics will occur against a backdrop of a moderate growth of global CKD anemia prevalent cases over the 10-year forecast period, with approximately 2.6 million drug treated cases across the 8MM in 2029.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global angina pectoris therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global angina pectoris market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global CKD anemia therapeutics market from 2019-2029.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AMAG Pharmaceuticals
American Regent
Amgen
Astellas
AstraZeneca
Bayer
FibroGen
GlaxoSmithKline
Johnson & Johnson
Kyowa Kirin
Mitsubishi Tanabe Pharma
Norgine BV
Pfizer
Roche
Rockwell Medical
Shield Therapeutics
Vifor Pharma

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 CKD-Induced Anemia: Executive Summary

2.1 CKD Anemia Market to Experience Strong Growth from 2019–2029

2.2 Optimizing Treatment Safety and Ease of Administration Are Popular R&D Strategies

2.3 New Pipeline Products Will Help in Partially Addressing Some Unmet Needs

2.4 Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Dominate the CKD Anemia Pipeline

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.4.3 Diagnosed Prevalent Cases of CKD Anemia and Diagnosed Prevalent Cases of CKD Anemia by Stage

5.4.4 Diagnosed Prevalent Cases of CKD Anemia Based on Dialysis Dependency

5.4.5 Diagnosed Prevalent Cases of CKD Anemia Based on Cause of Anemia

5.5 Epidemiological Forecast for CKD Anemia (2019–2029)

5.5.1 Diagnosed Prevalent Cases of CKD Anemia

5.5.2 Age-Specific Diagnosed Prevalent Cases of CKD Anemia

5.5.3 Sex-Specific Diagnosed Prevalent Cases of CKD Anemia

5.5.4 Diagnosed Prevalent Cases of CKD Anemia by Stage

5.5.5 Diagnosed Prevalent Cases of CKD Anemia Based on Dialysis Dependency

5.5.6 Diagnosed Prevalent Cases of CKD Anemia Based on Cause of Anemia

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Coronavirus Disease 2019 Impact

5.6.3 Limitations of the Analysis

5.6.4 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Erythropoiesis-stimulating agents (ESAs).

6.1.2 Iron Supplementation

6.2 US

6.3 5EU

6.4 Japan

6.5 China

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Safer Therapies that Avoid Overshooting Hb Targets

8.3 Alternative Therapies for Patients Resistant to ESAs

8.4 Therapies with Improved Route of Administration

8.5 Further Defining Appropriate Target Hb Levels

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHI)

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Amgen

10.4 Johnson & Johnson

10.5 Roche

10.6 Pfizer

10.7 Vifor Pharma

10.8 FibroGen

10.9 Akebia

10.10 AMAG Pharmaceuticals

10.11 Shield Therapeutics

10.12 Rockwell

10.13 GlaxoSmithKline

10.14 Bayer

10.15 JCR Pharmaceuticals

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 China

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Associate Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Reviewers

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: CKD Anemia: Key Metrics in the 8MM

Table 2: Stages of CKD

Table 3: Risk Factors and Comorbidities for CKD Anemia

Table 4: Treatment Guidelines for CKD Anemia

Table 5: Country Profile – US

Table 6: Country Profile – 5EU

Table 7: Country Profile – Japan

Table 8: Country Profile – China

Table 9: Leading ESA Treatments in CKD Anemia, 2021

Table 10: Amgen’s CKD Anemia Portfolio Assessment, 2021

Table 11: J&J’s CKD Anemia Portfolio Assessment, 2021

Table 12: Roche’s CKD Anemia Portfolio Assessment, 2021

Table 13: Pfizer’s CKD Anemia Portfolio Assessment, 2021

Table 14: Vifor Pharma’s Portfolio Assessment

Table 15: FibroGen’s CKD Anemia Portfolio Assessment, 2021

Table 16: Akebia’s CKD Anemia Portfolio Assessment, 2021

Table 17: AMAG’s CKD Anemia Portfolio Assessment, 2021

Table 18: Shield Therapeutics CKD Anemia Portfolio Assessment, 2021

Table 19: Rockwell CKD Anemia Portfolio Assessment, 2021

Table 20: GlaxoSmithKline’s CKD Anemia Portfolio Assessment, 2021

Table 21: Bayer’s CKD Anemia Portfolio Assessment, 2021

Table 22: JCR Pharmaceuticals’ CKD Anemia Portfolio Assessment, 2021

Table 23: CKD Anemia Market – Global Drivers and Barriers, 2019–2029

Table 24: Key Events Impacting Sales for CKD Anemia in the US, 2019–2029

Table 25: CKD Anemia Market – Drivers and Barriers in the US, 2019–2029

Table 26: Key Events Impacting Sales for CKD Anemia in the 5EU, 2019–2029

Table 27: CKD Anemia Market – Drivers and Barriers in the 5EU, 2019–2029

Table 28: Key Events Impacting Sales for CKD Anemia in Japan, 2019–2029

Table 29: CKD Anemia Market – Drivers and Barriers in Japan, 2019–2029

Table 30: Key Events Impacting Sales for CKD Anemia in China, 2019–2029

Table 31: CKD Anemia Market – Drivers and Barriers in China, 2019–2029

Table 32: Key Historical and Projected Launch Dates for CKD Anemia

Table 33: Key Historical and Projected Patent Expiry Dates for CKD Anemia

Table 34: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for CKD Anemia in 2019 and 2029

Figure 2: Analysis of the Company Portfolio Gap in CKD Anemia During the Forecast Period

Figure 3: Competitive Assessment of the HIF-PHIs that GlobalData Expects to Be Licensed for the Treatment of CKD Anemia During the Forecast Period

Figure 4: Mechanisms of CKD Anemia

Figure 5: 8MM, Diagnosed Prevalence of CKD Anemia, Men and Women, %, Ages ≥18 Years, 2019

Figure 6: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of CKD Anemia, Diagnosed Prevalent Cases of CKD Anemia by Stage, and Diagnosed Prevalent Cases of CKD Anemia Based on Dialysis Dependence

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CKD Anemia Based on Cause of Anemia

Figure 8: 8MM, Diagnosed Prevalent Cases of CKD Anemia, N, Both Sexes, Ages ≥18 Years, 2019

Figure 9: 8MM, Diagnosed Prevalent Cases of CKD Anemia by Age, N, Both Sexes, 2019

Figure 10: 8MM, Diagnosed Prevalent Cases of CKD Anemia by Sex, N, Ages ≥18 Years, 2019

Figure 11: 8MM, Diagnosed Prevalent Cases of CKD Anemia by Stage, N, Both Sexes, Ages ≥18 Years, 2019

Figure 12: 8MM, Diagnosed Prevalent Cases of CKD Anemia Based on Dialysis Dependence, N, Both Sexes, Ages ≥18 Years, 2019

Figure 13: 8MM, Diagnosed Prevalent Cases of CKD Anemia Based on Cause of Anemia, N, Both Sexes, Ages ≥18 Years, 2019

Figure 14: Unmet Needs and Opportunities in CKD Anemia

Figure 15: Overview of the Development Pipeline in CKD Anemia

Figure 16: Key Phase III Trials for the HIF-PHIs that GlobalData Expects to be Licensed for CKD Anemia in the 8MM During the Forecast Period

Figure 17: Competitive Assessment of HIF-PHIs that GlobalData Expects to be Licensed for the Treatment of CKD Anemia During the Forecast Period

Figure 18: Physicians Reporting Degree of Negative Impact of PRO2TECT Trial Results on Vadadustat Future Clinical and Market Potential

Figure 19: Analysis of the Company Portfolio Gap in CKD Anemia During the Forecast Period

Figure 20: Global (8MM) Sales Forecast by Country for CKD Anemia in 2019 and 2029

Figure 21: Global (8MM) Sales Forecast by Class for CKD Anemia in 2019 and 2029

Figure 22: Sales Forecast by Class for CKD Anemia in the US in 2019 and 2029

Figure 23: Sales Forecast by Class for CKD Anemia in the 5EU in 2019 and 2029

Figure 24: Sales Forecast by Class for CKD Anemia in Japan in 2019 and 2029

Figure 25: Sales Forecast by Class for CKD Anemia in China in 2019 and 2029

Frequently asked questions

Chronic Kidney Disease Anemia – Global Drug Forecast and Market Analysis to 2029 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Chronic Kidney Disease Anemia – Global Drug Forecast and Market Analysis to 2029 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chronic Kidney Disease Anemia – Global Drug Forecast and Market Analysis to 2029 in real time.

  • Access a live Chronic Kidney Disease Anemia – Global Drug Forecast and Market Analysis to 2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.